% Generated by roxygen2: do not edit by hand
% Please edit documentation in R/FitDat.r
\name{FitDat}
\alias{FitDat}
\title{Fit Historical Survival Data Assuming the Failure Time Follows the Weibull
Distribution}
\usage{
FitDat(data)
}
\arguments{
\item{data}{a historical survival data sample, has to contain two variables 'Time' and 'Cens': \cr
\emph{Time}, time under observation during trial for each patient.\cr
\emph{Cens}, the status indicator of patients (event = 1, censored = 0).}
}
\value{
\emph{fit.Weibull} Fitted models assuming Weibull distributions.\cr
\emph{AIC} AIC values from the fitted model. \cr
\emph{parameter.estimates} the estimated parameters from the fitted model.
}
\description{
The function fits parametric models with the underlying distributions assumed to be Weibull.
}
\examples{
library(IPDfromKM)
# a sample dataset that we already extracted from Wang et al, 2018.
df<- read.csv(system.file("extdata", "df.csv", package = "OneArm2stage"))

# risk time points
trisk <- c(0,2,4,6,8,10,12,14,16,18,20,22,24)

# number of patients at risk at each risk time point
nrisk.radio <- c(124,120,115,110,107,104,103,95,46,18,11,8,0)

# Preprocess the raw coordinates into an proper format for reconstruct IPD
pre_radio <- preprocess(dat=df, trisk=trisk,
                     nrisk=nrisk.radio,totalpts=NULL,maxy=100)

#Reconstruct IPD
est_radio <- getIPD(prep=pre_radio,armID=0,tot.events=NULL)

# shift the IPD data into the proper format for 'FitDat()'
ipd <- est_radio$IPD
dat3 <- as.data.frame(cbind(rep(0, nrow(ipd)),ipd$time, ipd$status))
colnames(dat3) <- c("Entry", "Time", "Cens")

# use FitDat function to fit the historical dat
modelSelect <- FitDat(dat3)
modelSelect$AIC
# Weibull
# 301.7776

# check the estimated parameters from the modeling results
modelSelect$parameter.estimates
# $Weibull
# shape     scale
# 0.1133671 3.9939753

}
\references{
Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D.,..., Robak, T. (2018).
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004):
a single-arm, multicentre, phase 2 trial. The Lancet, 391(10121), 659â€“667.
https://doi.org/10.1016/s0140-6736(17)33108-2
}
